Pembrolizumab,Pemetrexed,Cisplatin
Merck
['pembro', 'merck']
2. the cctg ind 227 study was supported by grants to cctg and merck &amp; co. inc. eligible pm patients were randomized 1:1 to cp with or without pembro. primary endpoint was median overall survival (mos). #asco23 #clinicaltrials
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer